Critics question FDA's endorsement of colchicine rival

01/18/2010 | Los Angeles Times (tiered subscription model)

Several rheumatologists and patient advocates are criticizing the FDA for granting market exclusivity to a rival of colchicine, an unapproved but widely used treatment for gout and familial Mediterranean fever. While the agency cited safety concerns as a reason for endorsing URL Pharma's Colcrys, opponents argued that the brand-name drug is no better or safer than the cheaper formulations and is much more expensive.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ